These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12527994)

  • 1. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.
    Grundmann K; Jaschonek K; Kleine B; Dichgans J; Topka H
    J Neurol; 2003 Jan; 250(1):63-6. PubMed ID: 12527994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors responsible for "aspirin resistance" - can we identify them?
    Postuła M; Tarchalska-Kryńska B; Filipiak KJ; Kosior D; Serafin A; Huczek Z; Opolski G
    Kardiol Pol; 2010 Apr; 68(4):403-11; discussion 412-3. PubMed ID: 20425699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
    Tobin WO; Kinsella JA; Collins DR; Coughlan T; O'Neill D; Egan B; Tierney S; Feeley TM; Murphy RP; McCabe DJ
    Br J Haematol; 2011 Mar; 152(5):640-7. PubMed ID: 21223254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
    Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici M; Mattle HP; Rothwell PM;
    Cerebrovasc Dis; 2009; 27(6):608-13. PubMed ID: 19407444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
    Gengo FM; Rainka M; Robson M; Gengo MF; Forrest A; Hourihane M; Bates V
    J Clin Pharmacol; 2008 Mar; 48(3):335-43. PubMed ID: 18223144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function.
    Bevilacqua S; Alkodami AA; Volpi E; Cerillo AG; Berti S; Glauber M; Gianetti J
    Ann Thorac Surg; 2009 Feb; 87(2):496-502. PubMed ID: 19161767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of aspirin resistance in patients with type 2 diabetes.
    Fateh-Moghadam S; Plöckinger U; Cabeza N; Htun P; Reuter T; Ersel S; Gawaz M; Dietz R; Bocksch W
    Acta Diabetol; 2005 Jun; 42(2):99-103. PubMed ID: 15944844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
    Sztriha LK; Sas K; Seres E; Boda K; Lenti L; Csifcsak G; Kovacs N; Vecsei L
    Acta Neurol Scand; 2008 Apr; 117(4):250-4. PubMed ID: 17961197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin non-responders in Thai ischemic stroke/TIA patients.
    Dharmasaroja P
    J Med Assoc Thai; 2008 Jun; 91(6):818-21. PubMed ID: 18697379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry.
    Tsantes AE; Mantzios G; Giannopoulou V; Tsirigotis P; Bonovas S; Rapti E; Mygiaki E; Kartasis Z; Sitaras NM; Dervenoulas J; Travlou A
    Thromb Res; 2008; 123(1):100-7. PubMed ID: 18430462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
    Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G
    Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
    Serebruany VL; Malinin AI; Sane DC; Jilma B; Takserman A; Atar D; Hennekens CH
    Eur J Pharmacol; 2004 Sep; 499(3):315-24. PubMed ID: 15381054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection.
    Modica A; Karlsson F; Mooe T
    J Thromb Haemost; 2007 Mar; 5(3):507-11. PubMed ID: 17319905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.